A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study tests whether denileukin diftitox will deplete regulatory T cells, boost tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or who are ineligible for front line therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center at San Antonio; Tyler Curiel
• Treatments: Denileukin diftitox; Interleukin-2

Criteria

Inclusion Criteria:

• Able to provide informed consent

• Not on Immune modulating drugs

• Life expectancy less than 6 months

Exclusion Criteria:

• Unable to tolerate phlebotomy

• Germ cell or stromal cell cancers of the ovaries

• Active autoimmune disease